{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/aluminium-hydroxide",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/aluminium-hydroxide#bnf_i1643857924652",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/aluminium-hydroxide#bnf_i1643857924652_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"aluminium hydroxide\" outputclass=\"int-heading-drug\">aluminium hydroxide</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of the active metabolite of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"baloxavir marboxil\" outputclass=\"int-drug\">baloxavir marboxil</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   aluminium hydroxide   might   decrease   the concentration of the active metabolite of   oral   baloxavir marboxil .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Baloxavir marboxil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/aluminium-hydroxide#bnf_i1643857924653",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/aluminium-hydroxide#bnf_i1643857924653_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"aluminium hydroxide\" outputclass=\"int-heading-drug\">aluminium hydroxide</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"chenodeoxycholic acid\" outputclass=\"int-drug\">chenodeoxycholic acid</ph>. <ph outputclass=\"int-action\">Manufacturer advises separating administration</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   aluminium hydroxide   decreases   the absorption of   chenodeoxycholic acid .  Manufacturer advises separating administration .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chenodeoxycholic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/aluminium-hydroxide#bnf_i1643857924654",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/aluminium-hydroxide#bnf_i1643857924654_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"aluminium hydroxide\" outputclass=\"int-heading-drug\">Aluminium hydroxide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"deferasirox\" outputclass=\"int-drug\">deferasirox</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Aluminium hydroxide   is predicted to   decrease   the exposure to   deferasirox .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deferasirox</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/aluminium-hydroxide#bnf_i1643857924655",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/aluminium-hydroxide#bnf_i1643857924655_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"aluminium hydroxide\" outputclass=\"int-heading-drug\">Aluminium hydroxide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"deferiprone\" outputclass=\"int-drug\">deferiprone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Aluminium hydroxide   is predicted to   decrease   the absorption of   deferiprone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deferiprone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/aluminium-hydroxide#bnf_i1643857924656",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/aluminium-hydroxide#bnf_i1643857924656_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"aluminium hydroxide\" outputclass=\"int-heading-drug\">Aluminium hydroxide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of blocked enteral or nasogastric tubes when given with</ph> <ph otherprops=\"enteral feeds\" outputclass=\"int-drug\">enteral feeds</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Aluminium hydroxide   increases   the risk of blocked enteral or nasogastric tubes when given with   enteral feeds .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enteral feeds</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/aluminium-hydroxide#bnf_i1643857924657",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/aluminium-hydroxide#bnf_i1643857924657_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"aluminium hydroxide\" outputclass=\"int-heading-drug\">Aluminium hydroxide</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"roxadustat\" outputclass=\"int-drug\">roxadustat</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"roxadustat\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/roxadustat.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP223244\">roxadustat</xref></ph> should be taken at least 1 hour after aluminium hydroxide</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Aluminium hydroxide   might   decrease   the exposure to   roxadustat .  Manufacturer advises  roxadustat  should be taken at least 1 hour after aluminium hydroxide .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Roxadustat</title>"
					}
				}
			],
			"hasSearchLabel": " Aluminium hydroxide  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/aluminium-hydroxide.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Aluminium hydroxide </title>"
			},
			"rdfs:label": "aluminium hydroxide"
		}
	]
}